Theravance Biopharma (TBPH) Misses Q4 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Needham & Company Reiterates Buy on Theravance Biopharma (TBPH) Following Conference Call
February 28, 2017 7:07 AM ESTNeedham & Company reiterated a Buy rating and $40.00 price target on Theravance Biopharma (NASDAQ: TBPH) following the company's 4Q conference call.
Analyst Alan Carr commented, "Theravance mgmt hosted a 4Q16 conference call late yesterday to provide a corporate update. We note several expected... More
